Publications

Ai W, Zuo Z. Synthesis, optimization and antitumor activity evaluation of sulfonyl benzoyl hydrazide derivatives as novel human LSD1 inhibitors. Bioorganic & medicinal chemistry letters. 2024. PMID: 39384076

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024. PMID: 39385035

Bhasin N, LeBlanc DM, Yates S, Eichbaum Q, Pham A, Sharma D, Zhang L, Vichinsky EP, Sarode R. Physician perspectives about the diagnosis and management of acute chest syndrome. Transfusion. 2024. PMID: 39373054

Vijayaraghavan M, Bonniot C, Satterfield J, Clark B, Xia F, Cheng C, Safier J, Pamatmat M, Schroeder SA. State Leadership Academies to reduce cigarette smoking among people with behavioral health conditions in the United States. Preventive medicine reports. 2024. PMID: 39670182

Ng DL, Vuhahula E, Kimambo AH, Ndayisaba MC, Philipo GS, Mushi BP, Ho KE, Paciorek A, Illonga Z, Zhang L, Vohra P, Weidler J, Bates M, Mmbaga EJ, Van Loon K. Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study. The Lancet. Oncology. 2024. PMID: 39369731

Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Haddadin M, Jain N, Jonas B, Kirby S, Liedtke M, Litzow M, Logan A, Long M, Luger S, Mangan JK, Massaro S, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Saygin C, Schwartz M, Shami P, Tomlinson B, Webster J, Awotiwon A, Stehman K. Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 39413812

Othman T, Logan AC, Muffly L, Leonard J, Park J, Shah B, Aldoss I. The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 39413830

Roy S, Malone S, Wing K, Chowdhury S, Kishan AU, Sun Y, Wallis CJD, Mohamad O, Jia AY, Swami U, Zaorsky NG, Morgan SC, Ong M, Agarwal N, Spratt DE, Small EJ, Saad F. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial. JAMA network open. 2024. PMID: 39405060

Kelly L. Schoenbeck, Anand Dhruva, Albert Lee, Anand Parikshak, Catherine Choy Smith, Neil P. Shah, Chloe Evelyn Atreya. Being Present-CML: A mindfulness-based intervention for patients with chronic myeloid leukemia taking tyrosine kinase inhibitors. Journal of Clinical Oncology. 2024. PMID:

Cui Z, Kang H, Li H, Lee ED, Lee YS, Peterson CN, Long SR, Grandis JR, Johnson DE. CYLD Alterations Are Associated With Metastasis and Poor Prognosis in Human Papilloma Virus-Positive Head and Neck Cancer. Head & neck. 2024. PMID: 39347568

Alway J, Gomez JO, Lee P, Cuby J, Chakravarty D, Vijayaraghavan M. Supporting Research Staff Working With People Experiencing Homelessness: Integrating Trauma-Informed and Resilience-Building Approaches Into Community-Engaged Research Studies. Health promotion practice. 2024. PMID: 39345050

Moore HN, Goncalves MD, Johnston AM, Mayer EL, Rugo HS, Gradishar WJ, Zylla DM, Bergenstal RM. Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care. Clinical breast cancer. 2024. PMID: 39462728

Gritti I, Wan J, Weeresekara V, Vaz JM, Tarantino G, Bryde TH, Vijay V, Kammula AV, Kattel P, Zhu S, Vu P, Chan M, Wu MJ, Gordan JD, Patra KC, Silveira VS, Manguso RT, Wein MN, Ott CJ, Qi J, Liu D, Sakamoto K, Gujral TS, Bardeesy N. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming. Cancer discovery. 2024. PMID: 39326063

Badros AZ, Foster L, Anderson LD, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin T, Voorhees PM. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2024. PMID: 39331724

Meher N, Bidkar AP, Wadhwa A, Bobba KN, Dhrona S, Dasari C, Mu C, Fong COY, Cámara JA, Ali U, Basak M, Bulkley D, Steri V, Fontaine SD, Zhu J, Oskowitz A, Aggarwal RR, Sriram R, Chou J, Wilson DM, Seo Y, Santi DV, Ashley GW, VanBrocklin HF, Flavell RR. PET Imaging Using 89Zr Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention (EPR) in Prostate Cancer. Molecular cancer therapeutics. 2024. PMID: 39331510

Oppegaard KR, Conley YP, Paul S, Cooper B, Harris CS, Shin J, Morse L, Levine JD, Cartwright F, Roy R, Melisko M, Kober KM, Hammer MJ, Miaskowski C. Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways. Journal of neural transmission (Vienna, Austria : 1996). 2024. PMID: 39325169

Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell reports. Medicine. 2024. PMID: 39368479

Chen H, Sarah L, Pucciarelli D, Mao Y, Diolaiti ME, Fujimori DG, Ashworth A. Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements. bioRxiv : the preprint server for biology. 2024. PMID: 39386707

Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan H, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 39321214

Chen H, Gou X, Mao Y, O'Leary PC, Diolaiti ME, Ashworth A. PARP7 Inhibitors and AHR Agonists Act Synergistically Across a Wide-Range of Cancer Models. Molecular cancer therapeutics. 2024. PMID: 39313957